


Live Bacterial Vectors



Innovative Administration Systems for Vaccines

December 19, 2003

Carol O. Tacket, M.D.

SPI-9 2 Mb

Types of Live Bacterial Vectors

- Those based on commensal bacteria
 - e.g., Lactobacilli
- Those based on attenuated pathogens
 - e.g., Salmonella, Shigella, BCG, Listeria

Salmonella enterica serovar Typhi vectors

 Bacteria express vaccine antigen by prokaryotic expression plasmids

or

 Bacteria deliver foreign genes carried on eukaryotic expression systems (DNA vaccines)

Pathogenesis of Typhoid Fever

- Oral ingestion of S. enterica serotype Typhi
- Passage through the gastric acid barrier
- Mucosal attachment and internalization via M cells overlying Peyer's patches
- Translocation to lymphoid follicles and mesenteric lymph nodes
- Primary (silent) bacteremia
- Seeding of liver, spleen, lymph nodes, gall bladder
- End of incubation period
- Secondary bacteremia and symptom onset



Putative Protective Immune Responses Elicited by S. Typhi Vector Antigens

- Mucosal IgA LPS O and flagellar H antibodies
- Serum LPS O and H antibodies
- Cell-mediated immunity:
 - Cytokine-producing (IFN-γ) proliferative lymphocytes
 - CTLs

Can analogous responses be elicited to the vectored antigen?

Licensed Ty21a is pretty good, but neither an ideal typhoid vaccine nor an ideal vaccine vector.

- Requires multiple doses for maximum immune response against S. Typhi
- Basis for attenuation is unknown.
- Clinical studies generally unsuccessful
 - Ty21a-Shigella sonnei O polysaccharide gave inconsistent protection against shigellosis.
 - Ty21a-V. cholerae Inaba LPS induced only modest rate of response to LPS.
 - Ty21a-H. pylori urease-weak T cells responses, no humoral response to urease.

Start over with wild-type S. Typhi Strain

Gene	Attenuating phenotype
aro	Dependence on nutrients not available in human host
cya crp	Deletion of global regulatory system
phoP/phoQ	Loss of response to environmental signals
htrA	Decreased ability to survive in macrophages
cdt	Interfere with ability to invade deep tissues
ssaV	Interrupt type III secretion system
Combinations	

Animal model S. Typhi is restricted to humans


- Murine typhoid
 - Oral infection of mice with S. Typhimurium or S.
 Enteriditis
- I.p. S. Typhi adsorbed to hog gastric mucin
 - S. Typhi infect and survive within peritoneal phagocytic cells.
 - Murine LD₅₀ of 10⁵
 - Mice survive about 48 hours.

Pre-clinical studies of S. Typhi vaccine strains in mice have not always correlated with the results of clinical trials.

Alternative animal model

- Murine intranasal model for assessing immunogenicity of S. Typhi strains
 - NALT induces responses to vector and heterologous antigen
 - Cell mediated and serologic responses

A Not-So-Delicate Imbalance



Ty800 Deleted in phoP phoQ

- Well tolerated in 11 volunteers in doses up to 10¹⁰ cfu
- No vaccine bacteremia
- Good immune responses


CVD 908-htrA Deleted in aroC aroD htrA

- No increased incidence of fever or diarrhea compared to placebo recipients
- No positive blood cultures
- Minimal fecal shedding (up to 3 days)
- Good immune responses
 - Antibody secreting cells
 - Serum antibody
 - Cell-mediated immunity

ZH9 Deleted in *ar*oC and *ssaV*

- Single dose of 10⁷-10⁹ well tolerated in 9 volunteers
- No bacteremia
- Brief shedding
- Good immune responses at the higher doses

The Optimal Balance



Antigens Expressed in Attenuated Salmonella Vectors in Humans

- Tetanus toxin fragment C
- Circumsporozoite protein (CSP) of *P. falciparum*
- Hepatitis B core and pre-S
- H. pylori urease

CVD 908-htrA(pTETIpp)-tetanus toxin fragment C

- 9 healthy adult volunteers
- Single dose of 10⁸⁻⁹ cfu
- No fever or bacteremia; some mild diarrhea and vomiting
- Decreased responses to S. Typhi LPS and H responses
- 3/9 who received 10⁸ cfu or more developed rises in serum antitoxin antibodies.

CVD 908-rCSP

- 10 volunteers
- Two doses of 5x10⁸, 8 days apart
- Strong S. Typhi LPS and H responses
- 2/10 had rises in serum anti-CSP
- 1/10 had CSP-specific CD8+ CTL

χ4632(pYA3167)-HBc-pre-S fusion

- 10 volunteers
- Single oral dose of 3 x 10⁷ or 7x10⁸
- Good responses to S. Typhi antigens at the higher doses
- No serum antibody to hepatitis pre-S or pre-S-specific ASC

Ty1033-urease

- 8 volunteers
- Single or double dose of 10¹⁰ cfu
- Strong S. Typhi LPS and H responses
- None of 8 had immune response to urease
- None of 3 had anti-urease response after oral booster of rUrease and LTB

Room for Improvement

- Selection of adequate plasmids and promoters to reduce metabolic burden to host bacteria
- Stabilization systems to allow adequate antigen expression
- Control of site of expression of antigen, i.e., cytoplasm or extracellular
- Preservation of conformation of antigen epitopes

Salmonella-vectored Vaccines for Rapid Deployment to Large Populations

- Yersinia pestis
- Anthrax
- Botulinum toxin

 ?part of a primeboost strategy with parenteral vaccine prime

Rapid deployment to large populations

- Ease of administration
- No needles/syringes
- No risk of transmission of human pathogens
- Mucosal immune responses; protect against infection as well • as disease?
- Multiple antigens in single strain
- Co-expression of immunomodulators (cytokines or adhesins)
- Public acceptance

- Cold chain requirement
- Need to monitor ingestion of whole dose of liquid formulation (esp. children)
- Probably unsafe for immunocompromised individuals
- Currently no clinical tests of Salmonella-based vaccine against agent of bioterror

Summary/Conclusions

- Several safe S. Typhi vectors identified in preliminary clinical studies
- Modest responses to foreign antigens in clinical studies of several S. Typhi vector strains
- Many possible strategies for improving immunogenicity